Details for Patent: 7,008,923
✉ Email this page to a colleague
Title: | Glycopeptide phosphonate derivatives |
Abstract: | Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. |
Inventor(s): | Leadbetter; Michael R. (San Leandro, CA), Linsell; Martin S. (San Mateo, CA) |
Assignee: | Theravance, Inc. (South San Francisco, CA) |
Filing Date: | Jan 18, 2005 |
Application Number: | 11/037,934 |
Claims: | 1. A method of treating a staphylococcal infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the formula: ##STR00009## or a pharmaceutically-acceptable salt thereof. 2. The method of claim 1, wherein the staphylococcal infection is caused by Staphylococcus aureus. 3. The method of claim 1, wherein the staphylococcal infection is caused by Staphylococcus epidermidis. 4. The method of claim 1, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus. 5. The method of claim 1, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis. 6. The method of claim 1, wherein the compound is administered intravenously. 7. The method of claim 1, wherein the pharmaceutically-acceptable salt is a hydrochloride salt. 8. A method of treating a staphylococcal infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula: ##STR00010## or a pharmaceutically-acceptable salt thereof. 9. The method of claim 8, wherein the pharmaceutical composition further comprises a cyclodextrin. 10. The process of claim 9, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin. 11. The process of claim 9, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin. 12. The method of claim 8, wherein the staphylococcal infection is caused by Staphylococcus aureus. 13. The method of claim 8, wherein the staphylococcal infection is caused by Staphylococcus epidermidis. 14. The method of claim 8, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus. 15. The method of claim 8, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis. 16. The method of claim 8, wherein the pharmaceutical composition is administered intravenously. 17. The method of claim 1, wherein the pharmaceutically-acceptable salt is a hydrochloride salt. 18. A method of treating a staphylococcal infection in a mammal where the infection is caused by methicillin-resistant Staphylococcus aureus, the method comprising administering a therapeutically effective amount of a composition comprising: (A) a compound of the formula: ##STR00011## or a hydrochloride salt thereof; and (b) hydroxypropyl-.beta.-cyclodextrin. |